Beyond Air Execs to Present at D. Boral Capital Global Conference
Event summary
- Beyond Air CEO Robert Goodman and CFO Dan Moorhead to participate in D. Boral Capital Global Conference 2026 on May 7.
- Event will feature one-on-one meetings with investors at The Plaza Hotel in New York.
- Beyond Air focuses on nitric oxide therapies, with FDA-approved LungFit PH for neonatal respiratory failure.
The big picture
Beyond Air's participation in the D. Boral Capital Global Conference underscores its focus on investor engagement amid commercial-stage growth. The company is positioning itself for broader market adoption of its nitric oxide-based therapies, particularly LungFit PH, in an increasingly competitive medical device and biopharmaceutical landscape. The event provides a platform to discuss its strategic and financial performance as it seeks to expand its customer base and maintain leadership in respiratory and neurological treatments.
What we're watching
- Commercial Strategy
- How Beyond Air will leverage investor engagement to accelerate LungFit PH adoption.
- Market Expansion
- Whether Beyond Air can sustain momentum in U.S. and international markets.
- Financial Performance
- The pace at which Beyond Air achieves long-term strategic and financial goals.
Related topics